This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Japan Tobacco Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Noriaki Shimoyama: Innovator in Janus Kinase Inhibitors
Introduction
Noriaki Shimoyama is a prominent inventor based in Takatsuki, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of Janus kinase inhibitors. His innovative work has led to advancements in therapeutic options for various diseases.
Latest Patents
Noriaki Shimoyama holds a patent for "Crystalline forms of a Janus kinase inhibitor." This invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A). The patent encompasses compositions, methods of preparation, methods of use, and methods of quantitation related to this compound. He has 1 patent to his name.
Career Highlights
Noriaki Shimoyama is currently employed at Japan Tobacco Inc., where he continues to engage in innovative research and development. His work has been instrumental in advancing the understanding and application of Janus kinase inhibitors in therapeutic settings.
Collaborations
Throughout his career, Noriaki has collaborated with notable colleagues, including Yukihiro Kamiya and Ryuhei Okura. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Noriaki Shimoyama is a key figure in the field of medicinal chemistry, particularly known for his work on Janus kinase inhibitors. His contributions have the potential to impact therapeutic strategies significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile